Surgical Treatment of Intraperitoneal Metastases From Lung Cancer

Two Case Reports and a Review of the Literature

Simone Sibio; Giuseppe Sigismondo Sica; Sara Di Carlo; Maurizio Cardi; Alessandra Di Giorgio; Bianca Maria Sollazzo; Paolo Sammartino


J Med Case Reports. 2019;13(262) 

In This Article


The occurrence of peritoneal metastases represents the clinical final stage of several tumors: most commonly ovarian, colorectal, gastric cancers, and, less frequently, appendix cancer. In recent years, the inclusion of cytoreductive surgery, alone or associated with locoregional chemotherapy, in the treatment strategy of some of these conditions has increased (peritoneal metastases from ovarian cancer or primary peritoneal malignancies), whereas its application remains mainly investigational in other conditions (gastric, colorectal, endometrial, and breast cancers).[1,2]

Lung cancer is one of the most common cancers worldwide. It is the leading cause of death from cancer; diagnosis is often made at an advanced stage when metastases have already spread to the other lung, to the liver, to the brain, to the bone, and to adrenal glands.[3]

Few reports are available in the literature about patients with peritoneal metastases from lung cancer.[4–6] Despite any treatment, overall survival for these patients is very poor, with reported rates of 9 months in a recent series.[5]

We describe two cases of diffused peritoneal metastases from lung cancer who underwent emergency cytoreductive surgery for bowel occlusion and had an unexpectedly good prognosis and long-term survival.